<DOC>
	<DOCNO>NCT00003646</DOCNO>
	<brief_summary>RATIONALE : Injecting allovectin-7 person 's melanoma cell may make body build immune response kill tumor cell . PURPOSE : Phase II trial study effectiveness gene therapy treat patient stage III stage IV melanoma respond previous treatment .</brief_summary>
	<brief_title>Gene Therapy Treating Patients With Stage III Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Demonstrate objective clinical response ( partial complete ) median duration least 4 month 15 % patient stage III IV melanoma treat Allovectin-7 . Allovectin-7 direct gene transfer immunotherapeutic agent . II . Determine benefit , risk , side effect Allovectin-7 patient population . PROTOCOL OUTLINE : This multicenter study . Patients receive intratumoral injection Allovectin-7 weekly 6 week . At week 9 , complete disease status assessment perform . Patients stable respond disease may receive additional course 6 injection . PROJECTED ACCRUAL : A total 70 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Histologically confirm melanoma ; Stage III locoregional disease , transit metastasis , nodal disease OR Stage IV metastatic disease skin , subcutaneous tissue , lymph node ( ) , and/or lung At least 1 metastasis surgery deem curative option Relapsed responded frontline chemotherapy biotherapy At least 1 measurable tumor least 1 cm 1 cm , less 5 cm 5 cm No history brain metastases visceral metastasis lung metastasis Prior/Concurrent Therapy Biologic therapy : See Disease Characteristics ; At least 4 week since prior biologic therapy Chemotherapy : See Disease Characteristics ; At least 4 week since prior chemotherapy Endocrine therapy : No concurrent immunosuppressive drug Radiotherapy : At least 4 week since prior radiotherapy Surgery : At least 2 week since prior major surgery Other : No concurrent anticancer drug therapy , experimental therapy Patient Characteristics Age : 18 Performance status : Karnofsky 80100 % Life expectancy : At least 6 month Hematopoietic : WBC least 3,000/mm3 ; Platelet count least 100,000/mm3 ; Hemoglobin least 9 g/dL Hepatic : Bilirubin great 2.0 mg/dL ; SGOT/SGPT le 3 time upper limit normal ; PT/PTT normal LDH albumin normal Renal : Creatinine great 2.0 mg/dL Cardiovascular : No uncontrolled hypertension ; No New York Heart Association class III IV disease Other : HIV negative ; Negative pregnancy test ; Fertile patient must use effective contraception ; No active autoimmune disease ; No active infection require parenteral antibiotic ; No uncontrolled diabetes mellitus ; No prior malignancy past 5 year except skin cancer stage 0II cervical cancer ; No significant psychiatric disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>adult solid tumor</keyword>
	<keyword>body system/site cancer</keyword>
	<keyword>cancer</keyword>
	<keyword>melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>skin tumor</keyword>
	<keyword>solid tumor</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>stage , melanoma</keyword>
</DOC>